Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CN-105
- Development stage
- Phase 2
- Lead developer
- AegisCN
- Modality
- Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
CN-105 is a neuroprotective pentapeptide with the sequence Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2. It acts as an apolipoprotein E (apoE) mimetic, targeting neuroinflammatory pathways. CN-105 is being developed for the treatment of cerebral hemorrhage, cognition disorders, and delirium. It is classified as a neuropeptide and neuroprotectant.
- Other names
- Ac-VSRRR-NH2Ac-VSRRR-NH-2Ac-VSRRR-NH 2N-Acetyl-L-valyl-L-seryl-L-arginyl-L-arginyl-L-argininamide
02
Targets
LRP1 (Prolow-density lipoprotein receptor-related protein 1)
Beyond the preview
Go deeper on CN-105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CN-105.